Cannabinoid CB2 Receptor Activation Attenuates Fentanyl-Induced Respiratory Depression Carmen A. Zavala, Ana C. Thomaz, Vishakh Iyer, Ken Mackie, and Andrea G. Hohmann Cannabis and Cannabinoid Research, 2021, Volume 6, Number 5, 389-400. DOI: 10.1089/can.2020.0059 Abstract Introduction : Overdose fatalities associated with the opioid epidemic are predictably attributable to druginduced respiratory depression. In terms of illicit opioid abuse, fentanyl is the synthetic opioid responsible for the largest number of overdose deaths. There is, therefore, an urgent need to identify safe and effective therapeutics that can attenuate fentanyl-induced respiratory depression. Identification of effective alternate analgesic strategies that lessen the respiratory depression associated with narcotics would also help [...]
Lire la suiteCannabinoid-2 Agonism with AM2301 Mitigates Morphine-Induced Respiratory Depression Beth M. Wiese, Erika Liktor-Busa, Aidan Levine, Sarah A. Couture, Spyros P. Nikas, Lipin Ji, Yingpeng Liu, Kenneth Mackie, Alexandros Makriyannis, Tally M. Largent-Milnes and Todd W. Vanderah Cannabis and Cannabinoid Research, 2021, Volume 6, Number 5, 401-412. Doi : 10.1089/can.2020.0076 Abstract Introduction : An escalating number of fatalities resulting from accidental opioid overdoses typically attributed to respiratory depression continue to define the opioid epidemic. Opioid respiratory depression results from a decrease in reflexive inspiration within the preBo¨ tzinger complex in the brainstem. Objective : Cannabinoid receptor agonism is reported to enhance opioid analgesia, yet whether cannabinoids enhance [...]
Lire la suiteThe effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD) Charlotte M. Pretzsch, Bogdan Voinescu, Maria A. Mendez, Robert Wichers, Laura Ajram, Glynis Ivin, Martin Heasman, Steven Williams, Declan GM Murphy, Eileen Daly and Gráinne M. McAlonan Journal of Psychopharmacology, 2019, Vol. 33, (9), 1141–1148 Doi : 10.1177/0269881119858306 Abstract Background : The potential benefits of cannabis and its major non-intoxicating component cannabidiol (CBD) are attracting attention, including as a potential treatment in neurodevelopmental disorders such as autism spectrum disorder (ASD). However, the neural action of CBD, and its relevance to ASD, remains [...]
Lire la suiteEffects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms : An Observational Study of 18 Participants Undergoing Compassionate Use Paulo Fleury-Teixeira, Fabio Viegas Caixeta, Leandro Cruz Ramires da Silva, Joaquim Pereira Brasil-Neto and Renato Malcher-Lopes Frontiers in Neurology, 2019, volume 10, Article 1146, 1-9. doi : 10.3389/fneur.2019.01145 Autism Spectrum Disorders comprise conditions that may affect cognitive development, motor skills, social interaction, communication, and behavior. This set of functional deficits often results in lack of independence for the diagnosed individuals, and severe distress for patients, families, and caregivers. There is a mounting body of evidence indicating the effectiveness of pure cannabidiol (CBD) and [...]
Lire la suiteStudy finds no evidence marijuana use increases stroke risk HealthDay News, 2020. https://www.upi.com/Health_News/2020/06/04/Study-finds-no-evidence-marijuana-use-increases-stroke-risk/3321591274273/?upi_ss=Cannabis An observational study conducted at hospitals found no evidence that marijuana use increases risk for stroke. File Photo by Atomazul/Shutterstock Whether pot use increases the risk of stroke has been hotly debated, and now a new study adds to evidence that it doesn't. "Our observational study looked specifically at recent cannabis use by reviewing drug testing data for people admitted to the hospital. While more research is needed with larger numbers of people, our study lends support to the studies showing that cannabis use does not increase the risk of stroke," said [...]
Lire la suiteNeuroprotective Effect of Cannabidiol Against Hydrogen Peroxide in Hippocampal Neuron Culture Jungnam Kim, Ji Yu Choi, Jeongyeon Seo, and Insung S. Choi Cannabis and Cannabinoid Research, 2021, Volume 6, Number 1, 40-48. Doi : 10.1089/can.2019.0102 Abstract Introduction : Reports on the neurotoxic and neuroprotective effects of cannabidiol (CBD) have not been in complete accord, showing different and somewhat contradictory results depending upon the brain cell types and experimental conditions employed. This work systematically examines the neuroprotective capability of CBD against oxidative stress (i.e., hydrogen peroxide [H2O2]) as well as its toxicity profile in the in vitro culture platform of primary hippocampal neurons. Materials and Methods : [...]
Lire la suiteReducing Effect of Cannabidiol on Alcohol Self-Administration in Sardinian Alcohol-Preferring Rats Paola Maccioni, Jessica Bratzu, Mauro A.M. Carai, Giancarlo Colombo, and Gian Luigi Gessa Cannabis and Cannabinoid Research, 2021, Doi : 10.1089/can.2020.0132 Abstract Introduction : Cannabidiol (CBD) is a major cannabinoid extracted from Cannabis sativa with no abuse potential. Data from recent rodent studies suggest that amelioration of alcohol-motivated behaviors may be one of the numerous pharmacological effects of CBD. This study was designed to contribute to this research, assessing the effect of CBD on operant oral alcohol self-administration in selectively bred Sardinian alcohol preferring (sP) rats, a validated animal model of excessive alcohol consumption. [...]
Lire la suiteProtective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions Nicole L. Stone, Timothy J. England, and Saoirse E. O’Sullivan Cannabis and Cannabinoid Research, 2021, Doi : 10.1089/can.2020.0159 Abstract Background and Objectives : Preclinical studies have shown cannabidiol is protective in models of ischemic stroke. Based on results from our recent systematic review, we investigated the effects of two promising neuroprotective phytocannabinoids, cannabigerol (CBG) and cannabidivarin (CBDV), on cells of the blood–brain barrier (BBB), namely human brain microvascular endothelial cells (HBMECs), pericytes, and astrocytes. Experimental Approach : Cultures were subjected to oxygen-glucose deprivation (OGD) protocol to model ischemic stroke and cell [...]
Lire la suiteCannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors Raquel Linge, Laura Jimenez-Sanchez, Leticia Campa, Fuencisla Pilar-Cuellar, Rebeca, Vidal, Angel Pazos, Albert Adell, Alvaro Diaz Neuropharmacology, 2016, 103, 16-26. doi : 10.1016/j.neuropharm.2015.12.017 Abstract Cannabidiol (CBD), the main non-psychotomimetic component of marihuana, exhibits anxiolytic-like properties in many behavioural tests, although its potential for treating major depression has been poorly explored. Moreover, the mechanism of action of CBD remains unclear. Herein, we have evaluated the effects of CBD following acute and chronic administration in the olfactory bulbectomy mouse model of depression (OBX), and investigated the underlying mechanism. For this purpose, we [...]
Lire la suiteCannabidiol has a unique effect on global brain activity: a pharmacological, functional MRI study in awake mice Aymen H. Sadaka, Ana G. Ozuna1, Richard J. Ortiz, Praveen Kulkarni, Clare T. Johnson, Heather B. Bradshaw, Bruce S. Cushing, Ai‑Ling Li, Andrea G. Hohmann and Craig F. Ferris Journal of Translationnal Medicine, 2021, 19, 220, 1-16. Doi : 10.1186/s12967-021-02891-6 Abstract Background : The phytocannabinoid cannabidiol (CBD) exhibits anxiolytic activity and has been promoted as a potential treatment for post-traumatic stress disorders. How does CBD interact with the brain to alter behavior? We hypothesized that CBD would produce a dose-dependent reduction in brain activity and functional coupling in [...]
Lire la suite